A Phase 1 Dose-Escalation Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Advanced Solid Tumors


Abstract

MEK162 had an acceptable safety profile at doses up to the MTD of 60 mg BID and showed preliminary signs of clinical activity. MEK162 displayed desirable PK properties with dose-dependent exposures and preliminary evidence of MEK-related PD marker changes.
Poster
non-peer-reviewed

A Phase 1 Dose-Escalation Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Advanced Solid Tumors


Author Information


PDF Share